Prospective, randomized trial of drug-eluting stents [sirolimus, paclitaxel] vs. bare metal stents for the reduction of restenosis in bypass grafts.

Trial Profile

Prospective, randomized trial of drug-eluting stents [sirolimus, paclitaxel] vs. bare metal stents for the reduction of restenosis in bypass grafts.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2011

At a glance

  • Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms ISAR-CABG
  • Most Recent Events

    • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Results published at the 60th Annual Scientific Session of the American College of Cardiology.
    • 04 Jan 2011 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top